Examining STIM1 Protein Levels in Autoimmune Disease Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the expression of STIM1 in the plasma membrane of lymphocytes from patients diagnosed with various autoimmune diseases. By identifying the levels of STIM1, researchers hope to uncover new pathologies that exhibit an over-expression of this protein. The findings could pave the way for future research and development of anti-STIM1 antibodies targeted at these autoimmune conditions. The study will involve patients from multiple hospital locations in Brittany and Martinique.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of one of the autoimmune diseases

Exclusion Criteria:

* Treatment with rituximab in the previous 12 months

Where it's running

• CHRU de Brest - Service de rhumatologie
  Brest, Brest, France Recruiting
• Centre Hospitalier des Pays de Morlaix
  Morlaix, Brittany Region, France Recruiting
• Centre Hospitalier de Quimper
  Quimper, Brittany Region, France Recruiting
• CHU de Martinique
  Fort-de-France, Martinique, France Recruiting

Study contacts

• Study coordinator: Divi Cornec
• Email: divi.cornec@chu-brest.fr
• Phone: 02 98 22 33 33

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• AMX0035 in adults with Type 1 Diabetes

  This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.

  Recruiting Phase 2 University of Washington · Seattle, Washington and 1 other locations · NCT07699380

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.